Andere talen BioAtla, Inc.

Aandelen

BCAB

US09077B1044

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
2,54 ^USD	+12,89%		+20,67%	+3,25%

27/03	BIOATLA, INC. : HC Wainwright handhaaft koopadvies	ZM
26/03	Transcript : BioAtla, Inc., Q4 2023 Earnings Call, Mar 26, 2024

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	24/04
BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress	26/03
BioAtla, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	26/03
BioAtla to Announce Fourth Quarter and Full-Year 2023 Financial Results and Provide Business Highlights on March 26, 2024	19/03
BioAtla Announces Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting	07/03
Sector Update: Health Care Stocks Rise in Late Afternoon Trading	21/12
Sector Update: Health Care Stocks Advance in Afternoon Trading	21/12
BioAtla Rallies After CEO Buys 50,000 Shares	21/12
BioAtla to Participate in the 42nd Annual J.P. Morgan Healthcare Conference	20/12
BioAtla, Inc.(NasdaqGM:BCAB) dropped from NASDAQ Biotechnology Index	15/12
BioAtla Hosting Virtual R&D Day to Highlight BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types	13/12
Bioatla Hosting Virtual R&D Day to Highlight Ba3071 Cab-Ctla-4 Phase 1 Data in Multiple Solid Tumor Types	13/12
BioAtla to Host Virtual R&D Day to Review BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types on Wednesday, December 13, 2023	06/12
Sector Update: Health Care Stocks Slipping Tuesday Afternoon	05/12
BioAtla Says Clinical Benefits, Safety Profile Support Further Evaluation of Potential Lung Cancer Therapy	05/12
BioAtla Presented Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event	05/12
BioAtla Presented Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event	05/12
BioAtla, Inc. Presents Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event	05/12
BioAtla to Participate in the JMP Securities Hematology and Oncology Summit	30/11
BioAtla to Host Virtual KOL Event to Review IASLC Data on BA3011 in NSCLC	28/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen BioAtla, Inc.

Aandelen

BCAB

US09077B1044

Andere talen

Filters